Paul Peter Tak

This profile gathers the share dealings of Paul Peter Tak in Candel Therapeutics, Inc., where the filings describe the role as chief executive. The record holds 18 filings, for trades running from 29 July 2021 to 11 September 2026.

Both buying and selling appear: 3 purchases worth €197k, against 9 sales worth €3.7M. Sales outweigh purchases by €3.5M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 2 option exercises. 2026 to date brings no purchases and 2 sales.

The median purchase comes to €24k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 11 September 2026: an option exercise of €167k, in Candel Therapeutics, Inc. The last purchase on record was published on 12 December 2022, which is 1,411 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.